Strategic Treatment Sequence Planning - Immunohistochemistry (IHC) Interpretation and Consultation (9 Markers)

A strategic treatment sequencing package is available. It is based on integrated and network analysis of nine immunohistochemical (IHC) markers selected to represent a complex biological system within a tumor. The goal is to understand the dynamic interactions between different pathways and how inhibiting one pathway may activate or inhibit another. This model is used to predict the optimal treatment sequence—that is, the order of treatments (A, B, C) that is likely to achieve the longest period of disease control while minimizing the toxicity of resistance. The package is reviewed by a committee comprising an oncologist, a molecular pathologist, and a clinical pharmacist.